{
  "denotations": [
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 34,
        "end": 38
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 74,
        "end": 92
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 97,
        "end": 100
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 170,
        "end": 177
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 182,
        "end": 185
      }
    },
    {
      "id": "T9",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 275,
        "end": 280
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 170,
        "end": 185
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21817190_8",
  "text": "CONCLUSIONS : The variants of the ITPA gene , which could protect against haemolytic anaemia and RBV dose reduction , were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B ."
}
